

<b>Reference:</b>	FOI.4041.20
<b>Subject:</b>	Biologic drugs
<b>Date of Request:</b>	21 September 2020

**Requested:**

1. Could you please provide the numbers of patients treated in the last 3 months by the Dermatology department (for any medical condition) with the following biologic drugs:
  - Adalimumab - Humira
  - Adalimumab Biosimilar
  - Apremilast
  - Brodalumab
  - Certolizumab
  - Dimethyl fumarate
  - Etanercept - Enbrel
  - Etanercept Biosimilar
  - Guselkumab
  - Infliximab - Remicade
  - Infliximab Biosimilar
  - Ixekizumab
  - Risankizumab
  - Secukinumab
  - Tildrakizumab
  - Ustekinumab
  
2. For the patients treated by the Dermatology department in the last three months with any of the above drugs, can you please provide the total number of paediatric (up to age 16) versus adult patients?
  
3. Could you please provide the numbers of patients treated in the last 3 months by the Gastroenterology department (for any medical condition) with the following biologic drugs:
  - Adalimumab - Humira
  - Adalimumab Biosimilar
  - Golimumab
  - Infliximab - Remicade
  - Infliximab Biosimilar
  - Tofacitinib
  - Ustekinumab
  - Vedolizumab

**Response:**

Hywel Dda University Health Board is unable to provide you with the information requested for question 1 and 2 as it is estimated that the cost of answering your request would exceed the "appropriate level" as stated in the Freedom of Information (Fees and Appropriate Limit) Regulations 2004.

The “appropriate level” represents the estimated cost of one person spending 18 hours or (2 ½ working days) in determining whether the UHB holds the information, and locating, retrieving and extracting the information.

In order to provide you with the number of patients that were prescribed the listed medications, the UHB would need to cross reference the dispensed medications with the patient records to identify the information requested.

The UHB is therefore applying an exemption under Section 12 of the Freedom of Information Act 2000, which provides an exemption from a public authority’s obligation to comply with a request for information where the cost of compliance is estimated to exceed the *appropriate limit*.

Under section 16 of the Freedom of Information Act 2000, the UHB has an obligation to provide advice and assistance. The UHB has therefore provided the number of medications dispensed by the Homecare team for questions 1 and 3.

1. The UHB provides, within the table below, the number of medications dispensed by the Homecare team for dermatology patients for the period 1 July 2020 to 1 October 2020.

Medication	Number dispensed
Adalimumab – Humira	2
Adalimumab Biosimilar	23
Apremilast	3
Brodalumab	0
Certolizumab	0
Dimethyl fumarate	0
Etanercept – Enbrel	0
Etanercept Biosimilar	2
Guselkumab	0
Infliximab – Remicade	0
Infliximab Biosimilar	0
Ixekizumab	1
Risankizumab	0
Secukinumab	13
Tildrakizumab	0
Ustekinumab	11

2. The UHB confirms that all of the patients treated by the dermatology department during the last three months, with any of the above listed drugs, were adults.
3. The UHB provides, within the table below, the number of medications dispensed by the Homecare team for gastroenterology patients for the period 1 July 2020 to 1 October 2020.

Medication	Number dispensed
Adalimumab – Humira	26
Adalimumab Biosimilar	33
Golimumab	0
Infliximab – Remicade	1
Infliximab Biosimilar	18
Tofacitinib	0

Ustekinumab	22
Vedolizumab	18